This week, CHEST issues guidelines for low-dose CT screening for lung cancer; severe COVID-19 survivors experience pulmonary impairment; the FDA approves Prograf to prevent lung transplant rejection; and more.
Read the full coverage here:
CHEST issues new guideline on benefits, harms, use of low-dose CT screening for lung cancer
Pulmonary impairment ‘highly prevalent’ in severe COVID-19 survivors following discharge
FDA approves Prograf to prevent organ rejection in lung transplant recipients
In omega-3 fatty acid trials, EPA alone yields greater CV risk reduction vs. EPA plus DHA
Benefit of full-dose heparin for patients with COVID-19 warrants ‘new standard of care’
References:
González J, et al. Chest. 2021;doi:10.1016/j.chest.2021.02.062.
Khan SU, et al. eClinical Medicine. 2021;doi:10.1016/j.eclinm.2021.100997.
Mazzone PJ, et al. Chest. 2021;doi:10.1016/j.chest.2021.06.063.
Sholzberg M, et al. medRxiv. 2021;doi:10.1101/2021.07.08.21259351.
